Acasti Pharma (ACST)
$0.43
0.01 (2.27%)
Acasti’s Losing Drug and ACST Stock Are Not for Weak Hearts
Acasti hopes a second study of its CaPre drug, due for release next month, shows better results, but most investors have left ACST stock.
11 Best Stocks to Buy for 2023

INSIDE: Investing legend Louis Navellier reveals his Top 11 Stocks for 2023 — FREE!
Download His Free Report Here:

Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:

Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:

Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:

Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
19.18M
PE Ratio
-1.26
EPS
-0.34
Volume (Avg. Vol.)
23,356
Day's Range
$0.42 - $0.44
52-Week Range
$0.34 - $1.35
Dividend & Yield
N/A (N/A)